Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.

@article{Kawaguchi2007SimultaneousIO,
  title={Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.},
  author={Wakae Kawaguchi and Hiroaki Itamochi and Junzo Kigawa and Yasunobu Kanamori and Tetsuro Oishi and Muneaki Shimada and Sinya Sato and Ruri Shimogai and Seiya Sato and Naoki Terakawa},
  journal={Cancer science},
  year={2007},
  volume={98 12},
  pages={2002-8}
}
Paclitaxel (PTX), one of the key drugs used to treat ovarian cancer, activates the Raf-mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3'-kinase (PI3K) pathways, both considered to be proliferation and cell-survival pathways. The present study aimed to clarify whether and how MEK and PI3K inhibitors affect sensitivity to PTX in ovarian cancer cells. We treated five ovarian cancer cell lines using PTX combined with MEK inhibitor (PD98059 [PD]) and PI3K inhibitor (LY294002… CONTINUE READING